BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
Dec 13, 2010
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Aclasta: Interim Phase III data

Novartis said it will withdraw regulatory applications in the U.S. and EU for Zometa for the adjuvant treatment of early breast cancer in premenopausal women after the IV bisphosphonate missed the primary endpoint in the open-label, international Phase III AZURE trial in 3,360 pre- and post-menopausal women. Adjuvant treatment with Zometa plus standard chemotherapy and/or hormonal therapy did not significantly improve disease-free...

Read the full 289 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >